Monotherapy trials with gabapentin for partial epilepsy.

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Partial-onset seizures are a common form of epilepsy.
• Monotherapy is a preferred treatment strategy for epilepsy when feasible.

Purpose of the Study:

• To evaluate the efficacy and safety of gabapentin (GBP) as monotherapy for partial-onset seizures.
• To compare different dosages of GBP and carbamazepine (CBZ) in seizure control.

Main Methods:

• Three large, multicenter, double-blind, parallel-group, dose-controlled trials were conducted.
• Patients with refractory or newly diagnosed partial seizures received varying doses of GBP or CBZ.
• Efficacy was assessed by time to exit due to seizure worsening or adverse events.

Main Results:

• In one trial, GBP monotherapy at 600 mg, 1200 mg, or 2400 mg daily showed no significant difference in time to exit for refractory epilepsy.
• In another trial, 3600 mg/day of GBP significantly increased time to exit compared to 300 mg/day in hospitalized patients.
• In newly diagnosed patients, 900 mg/day and 1800 mg/day of GBP showed longer time to exit than 300 mg/day, with similar completion rates and fewer adverse events than CBZ.

Conclusions:

• Gabapentin monotherapy is effective and safe for treating partial-onset seizures.
• Higher doses of gabapentin (900-3600 mg/day) appear more effective than lower doses.
• Gabapentin may offer a favorable safety profile compared to carbamazepine in certain patient populations.